AI Innovation and Market Restructuring in the Biotech Industry: The Ongoing Paradigm Shift in 2026
Editor
As of 2026, the biotech industry is experiencing unprecedented changes with the full-scale adoption of artificial intelligence technology. The global biotech market size is projected to grow by 12.1% from $1.32 trillion in 2025 to $1.48 trillion in 2026, with AI-based biotech solutions accounting for approximately $28 billion. Particularly in the field of drug development, the use of AI is rapidly increasing, fundamentally altering traditional pharmaceutical development processes. According to the latest report by McKinsey, AI-assisted drug development can reduce development time by 30-40% and improve early-stage success rates by 15-20% compared to traditional methods.
The Korean biotech industry is also undergoing rapid changes in line with these global trends. Samsung Biologics, based in Incheon, recorded sales of 1.24 trillion won in the fourth quarter of 2025, an 18.7% increase from the same period the previous year, and announced a 12% improvement in production efficiency with the introduction of an AI-based quality management system. Celltrion, also based in Incheon, is focusing on AI-assisted biosimilar development and expects to reduce development costs by approximately 15 billion won by applying AI predictive models to three pipelines slated for release in the first half of 2026. This indicates that Korean biotech companies are transitioning from simple contract manufacturing to becoming AI-driven innovative enterprises.
Global pharmaceutical giants have also reached unprecedented levels of AI investment. Swiss-based Roche invested $3.2 billion in AI research and development in 2025 and plans to expand this to $3.8 billion in 2026. Roche’s AI-based personalized therapy development platform is currently applied to 47 pipelines, with 12 of them entering Phase 2 clinical trials. U.S.-based Johnson & Johnson, located in New Jersey, increased its AI-related investment by 45% to $2.8 billion in 2025 compared to the previous year, focusing on AI-assisted biomarker discovery in the field of immuno-oncology.
The impact of AI in drug development is particularly pronounced. The traditional drug development process, which took an average of 10-15 years from target discovery to clinical trials, is being shortened to 7-10 years with the introduction of AI technology. AI like DeepMind’s AlphaFold3, which predicts protein structures, has predicted over 200 million protein structures, improving drug target discovery efficiency by 300% compared to traditional methods. Swiss-based Novartis successfully developed a treatment for rare diseases using AlphaFold technology, reducing development costs by approximately $200 million. These achievements demonstrate that AI is becoming a core engine in drug development, beyond being a mere auxiliary tool.
Rapid Growth of AI-Based Precision Medicine and Diagnostic Market
The application of AI technology in the medical diagnostic field is showing the fastest growth as of 2026. The global AI medical diagnostic market is expected to grow by 34% from $4.7 billion in 2025 to $6.3 billion in 2026, significantly outpacing the overall medical AI market growth rate of 22%. The accuracy of AI in imaging diagnostics has reached the level of human specialists, leading to a rapid increase in its clinical application. The U.S. FDA approved 127 AI-based medical devices in 2025, a 41% increase from the previous year.
Korea’s medical AI market is also experiencing rapid growth with active government support. According to the “Digital Healthcare Innovation Strategy” announced in December 2025, the Korean government plans to invest a total of 1.2 trillion won in the medical AI sector from 2026 to 2030. Of this, 40%, or 480 billion won, will be allocated to the development of AI-based diagnostic technologies, and 30%, or 360 billion won, to the establishment of personalized treatment platforms. Domestic medical AI companies such as Samsung Medison, Lunit, and VUNO are accelerating their global market entry with this government support, achieving notable success particularly in Southeast Asia and the Middle East markets.
The use of AI in precision medicine is opening new horizons for personalized treatment. Personalized treatment combining genomic analysis and AI is being most actively applied in cancer treatment, with the accuracy of predicting patient-specific treatment responses exceeding 85%. U.S.-based Pfizer, located in New York, invested $1.5 billion in 2025 in AI-assisted personalized cancer drug development, reporting more than a 30% improvement in efficacy across all six ongoing pipelines compared to existing standard treatments. This suggests that AI is revolutionizing not only diagnostics but also the treatment methods themselves.
Along with improved diagnostic accuracy, cost efficiency has also significantly improved. AI-based pathology diagnostic systems show more than a 50% cost reduction compared to traditional manpower-based diagnostics while maintaining an accuracy of over 95%. AI’s contribution is particularly notable in the diagnosis of rare diseases, where the average diagnosis period, previously 7.6 years, has been reduced to 2.3 years with AI adoption. These achievements directly contribute to improved healthcare accessibility and patient quality of life, leading to increased efficiency across the entire healthcare system.
Digital Transformation and Automation Innovation in Biomanufacturing
The adoption of AI and automation technologies is accelerating in the biomanufacturing sector. As of 2026, smart factory technology accounts for approximately $34 billion in the global biomanufacturing market, maintaining an annual growth rate of 28%. This is because traditional biomanufacturers are pursuing large-scale digital transformation to enhance production efficiency and strengthen quality management. The need for rapid mass production of vaccines and therapeutics has been highlighted since the COVID-19 pandemic, leading to a surge in automation investments by biomanufacturers.
Samsung Biologics announced a 15% improvement in production yield with the introduction of an AI-based integrated management system at its third plant in Incheon in 2025. This system reduced batch failure rates from 3.2% to 1.8% through real-time process monitoring and predictive quality management, creating an annual cost-saving effect of approximately 20 billion won. Additionally, the fourth plant, scheduled for completion in the second half of 2026, plans to establish a fully automated AI-based production line, expected to expand production capacity by 40% compared to the current level.
Global biomanufacturers are also making large-scale automation investments. U.S.-based AbbVie, located in Illinois, invested a total of $2.4 billion in 2025 to establish AI-based production management systems across 13 manufacturing facilities worldwide, reporting a 22% improvement in overall production efficiency. Particularly in the production of next-generation immuno-oncology drugs in response to Humira biosimilars, AbbVie utilized AI predictive models to automate production volume adjustments according to market demand, reducing inventory management costs by 30%. These achievements demonstrate that AI technology in biomanufacturing is being utilized as a strategic decision-making tool beyond mere automation.
AI’s contribution to quality management is particularly noteworthy. Due to the nature of biopharmaceuticals, even minor quality changes can lead to catastrophic results, making strict quality management essential. AI-based quality prediction systems can detect quality anomalies with 99.7% accuracy compared to traditional quality management methods. Swiss-based Roche reported a reduction in product recall rates from 0.08% to 0.02% after implementing an AI quality management system, preventing annual losses of approximately $120 million. Additionally, real-time quality monitoring reduced production downtime by 60% compared to previous levels.
The use of AI technology is also expanding in supply chain management. In the complex global supply chain of biopharmaceuticals, AI predictive analytics detect raw material supply instability in advance and suggest alternatives, minimizing production interruption risks. Johnson & Johnson announced an 18% reduction in raw material procurement costs through an AI-based supply chain optimization system in 2025, while simultaneously improving supply stability from 95% to 98.5%. These achievements indicate that biomanufacturers are pursuing digital transformation across the entire value chain beyond simple production optimization.
However, the AI innovation in the biotech industry faces several challenges. The biggest issue is the uncertainty of the regulatory environment. As regulatory guidelines for AI-based medical devices and drugs are not yet fully established, companies face difficulties in making investment decisions. The U.S. FDA announced plans to release a comprehensive regulatory framework for AI medical devices in the first half of 2026, but many uncertainties remain. Additionally, securing high-quality data necessary for AI development is a major challenge. Due to the sensitivity of medical data and privacy regulations, obtaining sufficient training data is not easy, acting as a constraint on improving AI model performance.
From an investment perspective, the biotech AI sector carries significant risks along with high growth potential. Venture capital investment in the global biotech AI sector reached $14.2 billion in 2025, a 31% increase from the previous year. However, the volatility of investment returns has also increased significantly, widening the gap between success and failure cases. Successful AI biotech companies show an average annual revenue growth rate of 40-50%, while most failed companies exit the market within 3-5 years, showing a polarization phenomenon. This suggests that investors need to comprehensively evaluate not only technological capabilities but also regulatory response capabilities, data acquisition capabilities, and commercialization strategies.
Looking at the outlook for the second half of 2026, the growth trend of the biotech AI market is expected to continue, but the pace of market structural changes is likely to accelerate. As large pharmaceutical companies internalize AI technology, pure AI biotech companies may find it difficult to survive without differentiated technology and proprietary data. On the other hand, companies that successfully integrate AI and biotech are expected to lead the market by creating new business models that transcend existing industry boundaries. Particularly, Korean companies are expected to leverage government support and their manufacturing-based strengths to secure global competitiveness in the field of biomanufacturing automation.
This content is for informational purposes only and should not be interpreted as investment solicitation or advice. Always consult a professional before making investment decisions.
